Baird raised the firm’s price target on Allogene Therapeutics (ALLO) to $9 from $7 and keeps an Outperform rating on the shares. The firm updated its model following data that suggest Cema-Cel strong showing in Futility analysis should spark enthusiasm.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics price target raised to $12 from $8 at H.C. Wainwright
- Allogene Therapeutics price target raised to $8 from $5 at Citizens
- Cellectis highlights Allogene ALPHA3 trial data, potential milestone payments
- Allogene Therapeutics Launches New Underwritten Common Stock Offering
- Allogene Therapeutics announces $175M common stock offering